article Open AccessTop 1% cited

Undertreatment of people with major depressive disorder in 21 countries

The British Journal of Psychiatry · 2016 · Vol. 210(2) · pp. 119–124

Graham Thornicroft✉(King's College London)Somnath Chatterji(King's College London)Sara Evans‐Lacko(King's College London)Michael J. Gruber(Harvard University)Nancy A. Sampson(Harvard University)Sergio Aguilar‐Gaxiola(King's College London)Ali Al-Hamzawi(King's College London)Jordi Alonso(Universitat Pompeu Fabra)Laura Helena Andrade(Universidade de São Paulo)Guilherme Borges(King's College London)Ronny Bruffaerts(King's College London)Brendan Bunting(University of Ulster)José Miguel Caldas‐de‐Almeida(King's College London)Silvia Florescu(King's College London)Giovanni de Girolamo(King's College London)Oye Gureje(King's College London)Josep María Haro(King's College London)Yanling He(Shanghai Jiao Tong University)Hristo Hinkov(King's College London)Elie G. Karam(King's College London)Norito Kawakami(King's College London)Sing Lee(Chinese University of Hong Kong)Fernando Navarro‐Mateu(King's College London)Marina Piazza(King's College London)José Posada‐Villa(King's College London)Yolanda Torres(King's College London)Ronald C. Kessler(Harvard University)

View via DOI Full-text PDF

Abstract

Only a minority of participants with MDD received minimally adequate treatment: 1 in 5 people in high-income and 1 in 27 in low-/lower-middle-income countries. Scaling up care for MDD requires fundamental transformations in community education and outreach, supply of treatment and quality of services.

Mental Health Treatment and Access Child and Adolescent Psychosocial and Emotional Development Maternal Mental Health During Pregnancy and PostpartumMajor depressive disorderOutreachMental healthPsychiatryMedicineDepression (economics)Economic growth

MeSH terms

AdolescentAdultAgedAged, 80 and overMajor Depressive DisorderDepressive Disorder, MajorFemaleHealth SurveysHumansMaleMental Health ServicesMiddle AgedPatient Acceptance of Health CareGlobal HealthPrevalence

Funding

Robert Wood Johnson Foundation
John D. and Catherine T. MacArthur Foundation
John W. Alden Trust
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
World Health Organization
South London and Maudsley NHS Foundation Trust
King's College Hospital NHS Foundation Trust
Government of the United Kingdom
Universidad CES
National Institute for Health and Care Research
King's College London
European Commission
Public Health Agency
Fundação de Amparo à Pesquisa do Estado de São Paulo
Generalitat de Catalunya
Bundesministerium für Gesundheit
National Insurance Institute of Israel
Ministerio de Salud de la Nación
Ministry of Health, Labour and Welfare
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Universidade de Lisboa
Ministerio de Ciencia y Tecnología
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
Servicio Murciano de Salud
Regione Piemonte
Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu
Servier
H. Lundbeck A/S
Fundação Champalimaud
Ministerio de Salud
Substance Abuse and Mental Health Services Administration
Pfizer Foundation
Pan American Health Organization
Executive Agency for Health and Consumers
Fundação para a Ciência e a Tecnologia
Instituto de Salud Carlos III
Consejería de Sanidad y Política Social, Comunidad Autónoma de la Región de Murcia
Departament de Salut, Generalitat de Catalunya
National Institute of Mental Health
National Institute on Drug Abuse
Fogarty International Center
Cilag